Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: University of Manchester, The Christie NHS Foundation Trust, CellCentric (United Kingdom), University of Oxford, MRC Weatherall Institute of Molecular Medicine, Western General Hospital, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Imperial College London, Beatson West of Scotland Cancer Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417015376
Cites:
Cited by:
Related to: